Investor · 2 deals
Every published round Welcome Ventures took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| AlleSense | Unnamed stage | 4 Aug 2026 | $5m | Lead | Startup Daily | |
| AlleSense | Series A | May 2026 | $5m | Lead | Startup Daily (29 May 2026), Dealroom, Startup Daily (28 May 2026) |
Companies Welcome Ventures has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| AlleSense | Biotech developing pathology imaging technology for early cancer detection | May 2026, Series A | 2 | 2 |
Fund closes reported for Welcome Ventures, as distinct from the investments it has made.
Companies Welcome Ventures has backed that another company then bought. An exit for the holding, not a deal Welcome Ventures did.
Stories naming Welcome Ventures. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech AlleSense, developing cancer pathology imaging tech, raised $5 million led by Welcome Ventures with Breakthrough Victoria and an AEA grant contributing.
La Trobe University spin-out AlleSense has secured $5 million to develop slide-based imaging for earlier cancer detection, led by Welcome Ventures with Breakthrough Victoria and the Australian Economic Accelerator's grant program also contributing.
Also Dealroom·Startup Daily
Breakthrough Victoria announces a $1 million investment in AlleSense, a La Trobe University spin-out developing nanofabricated slides for faster cancer diagnosis, joining round leader Welcome Ventures.